Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | PLAAT3 | P53816 | 3/20 | 0.53 |
| ▸ | PLAAT5 | Q96KN8 | 3/20 | 0.53 |
| ▸ | PLAAT2 | Q9NWW9 | 3/20 | 0.53 |
| ▸ | PLAAT4 | Q9UL19 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900705 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KMT2ALMNAMEN1 | |
| SCHEMBL4504434 | 0.91 | LMNA (0.48) | ALDH1A1SMN1; SMN2KMT2ALMNAMEN1 | |
| SCHEMBL4504437 | 0.91 | LMNA (0.48) | ALDH1A1SMN1; SMN2KMT2ALMNAMEN1 | |
| SCHEMBL4503675 | 0.87 | RAB9A (0.59) | ALDH1A1SMN1; SMN2KMT2ALMNAMEN1 | |
| SCHEMBL4503673 | 0.87 | RAB9A (0.59) | ALDH1A1SMN1; SMN2KMT2ALMNAMEN1 | |
| SCHEMBL4517907 | 0.87 | LMNA (0.55) | ALDH1A1SMN1; SMN2KMT2ALMNAMEN1 | |
| SCHEMBL4898673 | 0.87 | LMNA (0.55) | ALDH1A1SMN1; SMN2KMT2ALMNAMEN1 | |
| SCHEMBL4502890 | 0.86 | RAB9A (0.49) | ALDH1A1SMN1; SMN2KMT2ALMNAMEN1 | |
| SCHEMBL4491589 | 0.86 | LMNA (0.49) | ALDH1A1SMN1; SMN2KMT2ALMNAMEN1 | |
| SCHEMBL4897631 | 0.86 | RAB9A (0.49) | ALDH1A1SMN1; SMN2KMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494989-B2 | Pyridine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2008-03-20 | — | — | US | disclosed |
| US-7288544-B2 | Pyrimidine compounds useful as N-type calcium channel antagonists | AJINOMOTO CO., INC. (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | AJINOMOTO CO., INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1318147-A1 | NOVEL PYRIMIDINE DERIVATIVE AND NOVEL PYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | P2RY10, CACNA1B, CACNA1E | ALDH1A1 2263/4885SMN1; SMN2 758/4885KMT2A 4314/4885 |
| US-20040009991-A1 | Pyrimidine derivatives and new pyridine derivatives | CACNA1I, CACNA1B, CACNA1E | ALDH1A1 840/4885SMN1; SMN2 779/4885KMT2A 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.